Kargluminsyra Waymade

carglumic acid, the active ingredient in Kargluminsyra Waymade, is an N‑acetylglutamate analog presented as an oral formulation for oral use. It treats hyperammonemia in patients with N‑acetylglutamate synthase deficiency and serves as adjunct therapy for hyperammonemia in organic acidurias.

GNH USA supplies Kargluminsyra Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Kargluminsyra Waymade is used to manage disorders of the urea cycle and related hyperammonemia conditions. - Hyperammonemia due to N‑acetylglutamate synthase deficiency: reduces plasma ammonia levels and supports the urea cycle. - Hyperammonemia in organic acidurias (adjunct therapy): helps lower ammonia accumulation. - Urea cycle disorder therapy: facilitates nitrogen disposal in patients with impaired urea cycle function.

Adverse reactions may occur with carglumic acid therapy.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal pain - Headache - Fatigue

Serious or Rare Side Effects: - Anaphylactic reaction - Severe allergic dermatitis - Hepatic dysfunction - Metabolic acidosis - Seizures - Significant elevation of liver enzymes

Carglumic acid requires careful monitoring and specific safety measures. - Dose adjustment in renal impairment: monitor ammonia levels and renal function. - Monitor liver function: assess for signs of hepatic adverse events. - Avoid in patients with known hypersensitivity to carglumic acid or its excipients. - Use with caution in pregnancy or breastfeeding: limited data, weigh benefits against risks. - Store at below 25°C: keep in the original pack, protect from moisture.

Carglumic acid may interact with other medications that affect ammonia metabolism.

Major Interactions (Avoid): - Concurrent use with sodium phenylbutyrate: may diminish therapeutic effect. - Co‑administration with high‑dose nitrogen scavengers: risk of ammonia rebound.

Moderate Interactions (Monitor Closely): - Valproic acid: potential increase in ammonia levels. - Other urea cycle agents: monitor plasma ammonia closely. - Diuretics affecting electrolyte balance: observe for electrolyte disturbances.